Syncria meets Phase II endpoint

GlaxoSmithKline Inc. (LSE:GSK; NYSE:GSK) said data from a double-blind, Phase IIb trial in 356 patients with Type II diabetes showed that weekly, biweekly and monthly regimens of Syncria albiglutide all met the primary endpoint of a significant reduction from baseline in HbA1c at week 16 vs. placebo (0.8-0.9% vs. 0.2%, p<0.05 for each). With 30 mg Syncria once weekly, 52% of patients achieved the HbA1c goal of less than 7%, while 53% and 48% of patients taking 50 mg biweekly and 100 mg monthly Syncria achieved the goal, respectively, vs. 20% with placebo (p<0.05 for each). In an open-label reference arm of 35 patients who received twice-daily exenatide, HbA1c decreased by 0.5% from baseline and 35% achieved the HbA1c goal.

Patients received subcutaneous placebo; Syncria weekly (4, 15 or 30 mg), biweekly (15, 30 or 50 mg) or monthly (50 or 100 mg); or exenatide for 16 weeks. Data were presented at the American Diabetes Association meeting in New Orleans. ...